Idiopathic Pulmonary Fibrosis Treatment Market Growth, Demand and Challenges of the Key Industry Players 2024-2032
                     Global Idiopathic 
Pulmonary Fibrosis 
Treatment Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A cc o r d i ng  t o  t h e  l a te s t  r e p o r t  b y  IM A R C  G r o up ,  t i t l e d  " Id i o p a t h i c  P u l m o n a r y  F ib r o s is  
T re a t m e n t  M ar k e t :  G l o b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  
F o r e c a s t  2 0 2 4 -2 0 3 2 , "  t h e  g l o b a l  i d i o p a t h i c  p u l mo n a r y  f i b r o s i s  t r e a t m e n t  m a rk e t  s i z e  
r ea c h e d  U S $  3 , 8 4 8 .3  M i l l i o n  i n  2 0 2 3 .
Report I d i o p a t h i c  p u l m o n a r y  f i b r o s i s  ( I P F )  i s  a n  i n t e rs t i t i a l  l u n g  d i s e as e  t h a t  c a u se s  s c a r r i ng  o f  t h e  l u n g s ,  r e d uc i n g  th e i r  o xy g e n  d e l i v e r i n g  c ap a c i t y .  T he  c h r on i c  l un g  d i se a s e  i s  
p r o g r e s s i v e  a n d  i r r e v e r s i b l e  i n  n a t u r e  a s  i t  c on t i n u o u s l y  i m pa c t s  t h e  fu n c t i on i n g  o f  t he  
Highlight and l u n gs .  I t  c a us e s  d i f f i cu l t y  i n  b r e a th i n g  a n d  d oe s  n o t  p r ov i d e  s u f f i c i e n t  o xy g e n  t o  d i f f e r e n t  b o d y  p a r t s .  
I P F  ca n  b e  d i ag n o s ed  t h r o ug h  c h e s t  i m a g i n g  s t ud i e s ,  l u n g  b i o p s i es ,  p u l mo n a r y  f u n c t i on  
Description t e s t s ,  a n d  a n t i b o d y  t e s t s .  T he  t re a t m en t  i n c l ud e s  n i n t e d a n i b  a n d  p i r f e n i d o n e - b a s e d  
d r u g s  t h a t  a i d  i n  l u n g  f u nc t i o n i n g  a n d  m i n i m i z e  th e  r i s k  o f  a c u t e  r es p i r a t o ry  
de t e r i o r a t i o n .  T he y  a r e  a l s o  o f fe r e d  a l on g  w i t h  ox y g e n  th e r a p y  a n d  p a l l i a t i ve  c a r e ,  
w h i c h  i mp r o v e  t h e  ch a n c e s  o f  r ec o v e r y  a n d  p r o v i d e  c o m fo r t  t o  t h e  p a t i e n t .
R eq u e s t  f o r  a  P D F  sa m p le  o f  th i s  r ep o r t :  
h t t p s : / /w w w . i ma r c g r o u p . co m / i d i op a t h i c -p u l m o na r y - f i b r o s i s - t r e a tm e n t - ma r k e t / r e qu e s t s a
mp l e
Report Description
G l ob a l  I d i opa t h i c  Pu l m ona ry  F i b ros i s  T r ea t m ent  M ark e t  T rend s :
The  m ar k e t  i s  p r i m ar i l y  d r i ven  by  t h e  r i s i ng  ge r ia t r i c  popu l a t i on ,  wh ich  i s  sus cep t ib le  t o  l ung  d i so r d e r s .  Ag ing  i s  
cons i de r ed  t he  g r ea t es t  r i s k  f ac t o r  f o r  t h e  deve lopm en t  o f  I P F .  M o r eove r ,  t he  g r ow in g  p r ev a lence  o f  f i b r o t i c  d i s eases ,  
ow ing  t o  c hang in g  l i f es t y les  and  he avy  cons um pt ion  o f  n i co t i ne  p r oduc t s  l i k e  c ig a r e t t es  i s  a l s o  p r ope l l i ng  t he  de m an d  f o r  
I PF  t r ea t m en t .  
Bes ide s  t h i s ,  m a jo r  hea l t hca r e  com pan i es  a r e  e x t en s i ve l y  i nves t i ng  i n  t he  dev e lopm en t  an d  com m er c i a l i za t i on  o f  nove l  
d r ugs ,  esp ec ia l l y  i n  em er g in g  econ om ie s ,  wh ic h  i s  f ue l i ng  t he  g r ow t h  o f  t he  m ar k e t .  The  r i s i ng  he a l t h  con sc iou sness  
am o ng  in d i v idu a l s  r ega r d ing  e f f ec t i v e  m ana gem e n t  s t r a t eg ie s  i s  a l so  c r ea t i n g  a  pos i t i ve  ou t l o ok  f o r  t he  m ar ke t .  
Fu r t h e r m o r e ,  i nc r e as ing  hea l t hca r e  ex pend i t u r es  and  im pr ov ing  i n f r as t r uc t u r e  a r e  a l so  f ac i l i t a t i ng  t he  m ar k e t  g r ow t h .
Look i ng  f o rw ard ,  t he  ma rke t  va l ue  i s  expe c t ed  t o  re ach  US $  6 , 9 80 . 4  M i l l i on  b y  20 32 ,  e xh i b i t i ng  a  CAG R o f  6 . 6%  
dur i ng  t h e  f o r ecas t  pe r i od  ( 2024 - 203 2 ) .
V i ew  R epor t  TO C,  F i g ures  and  Ta b l es :  
h t t p s : / / w w w . i m arcgr oup . c om / i d i o pa t h i c - pu l mon ary - f i b ro s i s - t rea t men t - m ar ke t
Breakup by Drug Class:
• MAPK Inhib itors
• Tyrosine Inh ibitors
• Autotaxin Inhibitors
 
Breakup by End User:
• Hospitals
Report • Long-term Care Fac i l i t ies
Segmentation • Others
Breakup by Region:
• North America
• Asia-Pacifi c
• Europe
• Lat in America
• Middle East and Afr ica
• AdAlta Pty Ltd.
• Angion Biomedica Corp.
• Boehr inger Ingelheim Internat ional GmbH (C.  
H.  Boehr inger  Sohn AG & Co.  KG)
Competitive • Bristo l -Myers Squibb Company
• Cipla Inc.
Landscape • F.  Hoff mann-La Roche AG (Roche Holding AG)
with Key • Fibrogen Inc.
• Galapagos NV
Players
• Liminal B ioSciences Inc.
• Medicinova Inc.
• Merck & Co.  Inc.
• Novart is  AG
• Vectura Group Plc.
How has the global idiopathic pulmonary fibrosis treatment 
market performed so far and how will it perform in the 
coming years?
What has been the impact of COVID-19 on the global 
idiopathic pulmonary fibrosis treatment market?
What are the key regional markets?
Key 
Questions What is the breakup of the market based on the drug class?
Answered in What is the breakup of the market based on the end user?
the Report What are the various stages in the value chain of the 
industry?
What are the key driving factors and challenges in the 
industry?
What is the structure of the global idiopathic pulmonary 
fibrosis treatment market and who are the key players?
What is the degree of competition in the industry?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  I d i o p a t h i c  P u l m o n a r y  F i b r o s i s  T r e a t m e n t  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  D r u g  C l a s s
    6 . 1     M A P K  I n h i b i t o r s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  M a r k e t  F o r e c a s t
    6 . 2     T y r o s i n e  I n h i b i t o r s
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  M a r k e t  F o r e c a s t
    6 . 3     A u t o t a x i n  I n h i b i t o r s
        6 . 3 . 1  M a r k e t  T r e n d s
        6 . 3 . 2  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  E n d  U s e r
       
    7 . 1     H o s p i t a l s
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     L o n g - t e r m  C a r e  F a c i l i t i e s
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
    7 . 3    O t h e r s
        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  R e g i o n
    8 . 1     N o r t h  A m e r i c a
        8 . 1 . 1  U n i t e d  S t a t e s
Table of            8 . 1 . 1 . 1  M a r k e t  T r e n d s           8 . 1 . 1 . 2  M a r k e t  F o r e c a s t
        8 . 1 . 2  C a n a d a
           8 . 1 . 2 . 1  M a r k e t  T r e n d s
Contents            8 . 1 . 2 . 2  M a r k e t  F o r e c a s t    8 . 2     A s i a  P a c i f i c
        8 . 2 . 1  C h i n a
           8 . 2 . 1 . 1  M a r k e t  T r e n d s
           8 . 2 . 1 . 2  M a r k e t  F o r e c a s t
        8 . 2 . 2  J a p a n
           8 . 2 . 2 . 1  M a r k e t  T r e n d s
           8 . 2 . 2 . 2  M a r k e t  F o r e c a s t
        8 . 2 . 3  I n d i a
           8 . 2 . 3 . 1  M a r k e t  T r e n d s
           8 . 2 . 3 . 2  M a r k e t  F o r e c a s t
        8 . 2 . 4  S o u t h  K o r e a
           8 . 2 . 4 . 1  M a r k e t  T r e n d s
           8 . 2 . 4 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
ht t ps : / /w ww. i ma rc gro up . c o m / i d i o pa t h i c -p u lm o na ry -fi bro s i s - t r
ea t m ent -m a rke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: